CryoLife Inc. [NYSE: CRY] jumped around 0.64 points on Friday, while shares priced at $17.38 at the close of the session, up 3.82%. The company report on September 8, 2020 that CryoLife to Present at the 18th Annual Morgan Stanley Global Healthcare Conference.
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference.
CryoLife’s management team will present at the virtual investor conference on Wednesday, September 16, 2020. The Company’s virtual fireside chat is scheduled to begin at 11:00 a.m. ET. A live webcast of the virtual fireside chat will be accessible through CryoLife’s website, www.cryolife.com, on the Investor Relations page. An archived copy of the webcast will be available for 90 days on the same website. .
CryoLife Inc. stock is now -35.84% down from its year-to-date (YTD) trading value. CRY Stock saw the intraday high of $18.98 and lowest of $17.28 per share. The company’s 52-week high price is 31.77, which means current price is +37.61% above from all time high which was touched on 01/29/20.
Compared to the average trading volume of 391.51K shares, CRY reached a trading volume of 1614083 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CryoLife Inc. [CRY]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRY shares is $26.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRY stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
First Analysis Sec have made an estimate for CryoLife Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 14, 2020. While these analysts kept the previous recommendation, Canaccord Genuity dropped their target price from $32 to $29. The new note on the price target was released on February 14, 2020, representing the official price target for CryoLife Inc. stock. Previously, the target price had yet another raise from $30 to $38, while Needham kept a Buy rating on CRY stock.
The Average True Range (ATR) for CryoLife Inc. is set at 0.81, with the Price to Sales ratio for CRY stock in the period of the last 12 months amounting to 2.46. The Price to Book ratio for the last quarter was 2.20, with the Price to Cash per share for the same quarter was set at 3.44. Price to Free Cash Flow for CRY in the course of the last twelve months was 134.82 with Quick ratio for the last quarter at 4.60.
How has CRY stock performed recently?
CryoLife Inc. [CRY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.53. With this latest performance, CRY shares dropped by -15.47% in over the last four-week period, additionally plugging by 18.15% over the last 6 months – not to mention a drop of -39.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRY stock in for the last two-week period is set at 39.45, with the RSI for the last a single of trading hit 39.34, and the three-weeks RSI is set at 39.74 for CryoLife Inc. [CRY]. The present Moving Average for the last 50 days of trading for this stock 19.25, while it was recorded at 16.78 for the last single week of trading, and 22.48 for the last 200 days.
CryoLife Inc. [CRY]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and CryoLife Inc. [CRY] shares currently have an operating margin of +7.01 and a Gross Margin at +62.33. CryoLife Inc.’s Net Margin is presently recorded at +0.62.
Return on Total Capital for CRY is now 3.76, given the latest momentum, and Return on Invested Capital for the company is 0.33. Return on Equity for this stock inclined to 0.61, with Return on Assets sitting at 0.29. When it comes to the capital structure of this company, CryoLife Inc. [CRY] has a Total Debt to Total Equity ratio set at 85.81. Additionally, CRY Total Debt to Total Capital is recorded at 46.18, with Total Debt to Total Assets ending up at 40.48. Long-Term Debt to Equity for the company is recorded at 83.27, with the Long-Term Debt to Total Capital now at 44.82.
Reflecting on the efficiency of the workforce at the company, CryoLife Inc. [CRY] managed to generate an average of $1,423 per employee. Receivables Turnover for the company is 5.15 with a Total Asset Turnover recorded at a value of 0.47.CryoLife Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 5.90.
Earnings analysis for CryoLife Inc. [CRY]
With the latest financial reports released by the company, CryoLife Inc. posted 0.06/share EPS, while the average EPS was predicted by analysts to be reported at 0.05/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 20.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CryoLife Inc. go to 2.00%.
Insider trade positions for CryoLife Inc. [CRY]
There are presently around $572 million, or 89.00% of CRY stock, in the hands of institutional investors. The top three institutional holders of CRY stocks are: BLACKROCK INC. with ownership of 5,972,740, which is approximately 5.326% of the company’s market cap and around 3.20% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 2,947,990 shares of the stock with an approximate value of $51.24 million in CRY stocks shares; and VANGUARD GROUP INC, currently with $42.58 million in CRY stock with ownership of nearly 0.296% of the company’s market capitalization.
Positions in CryoLife Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 64 institutional holders increased their position in CryoLife Inc. [NYSE:CRY] by around 3,380,402 shares. Additionally, 47 investors decreased positions by around 1,438,200 shares, while 30 investors held positions by with 28,114,270 shares. The mentioned changes placed institutional holdings at 32,932,872 shares, according to the latest SEC report filing. CRY stock had 13 new institutional investments in for a total of 253,784 shares, while 14 institutional investors sold positions of 252,914 shares during the same period.